Pharmaceuticals
Long in NVO Established There are several aspects to this chart- the wave analysis is certainly up for debate, but what remains is improving fundamentals.
On this chart we have a corrective sequence ABC starting in 2014 and concluding in early 2017. On this chart, we can see the 30 day MA volume skyrockets in the beginning of 2017. This corresponds to the timing of the Obama administration focusing their healthcare attacks on big pharma, specifically drug pricing. We can even see a faint busted head and shoulders on this chart, with the right shoulder being broken by terrible guidance on earnings
At the peak in 2015, we also see a peak in operating profit margin. Over the next 12 month fundamentals began to draw back with book value/share, liquidity ratios, and margins all slowly declining. As Obamacare got pushed through US congress (where over 50% of revenue is earned), the outlook looked bleak. Then the Man who lives above the Guchi Store was elected, and big pharma saw hope on the horizon and began surging higher. This was a false bull market though; margins and liquidity ratios were not improving for NVO.
Then the surprise happened, President Trump began attacking pharma. Combined with the already volatile stock market NVO plunged to a correction right at the .618 fibonnaci level, if it maintains this as the low a perfect sign that the 2 impulse wave has just completed.
Where we stand now:
Novo Nordisk, one of the largest pill pushers was forced to lower outlooks with increasing competition from generics. With this pressure, the company has been forced to cut many US jobs and refocus R&D spending, rendering some patents and research useless. Over the last few years they've been forced to impair assets for use on their income statement, but NVO still maintains a 2.29 P/Tangible Book ratio, (better than peers: GSK, BMY, LLY). Gross margins have begun improving and P/S has landed at one of the lowest, if not the lowest level in the peer group. Improvement on the liquidity measures could send this stock flying, but most importantly is the deadlock that could ensue in congress. Recently one of the up-and-coming generics plunged as the FDA put a hold on their diabetes drug trial.
I took a long position in NVO on 11/27 and plan on holding this until I either get stopped out at 44 or we rally to previous highs
Loxo - Bull pennant and upcoming eventsThis is the weekly chart on Loxo Oncology. This biotech focuses on cancer treatments by targeting genetic mutations that create protein chimers that lead to unregulated cellular proliferation. In English, and very simply, imagine a copy machine. When you press 'Copy' you should get one duplicate of the item you want copied. Cells have similar systems where a protein in the cell membrane receives a signal from the outside world telling the cell to divide and make a copy of itself.
Now imagine your copy machine crosses circuits with a 'Repeat' button. This will lead to infinite, unchecked copying. In cancer a similar thing occurs. Genetic mutations can cause the growth signalling protein to get joined to other proteins leading to unchecked, infinite cellular proliferation. This is one of the several steps to developing cancer. Loxo has developed and is testing drugs that target these specific mutations.
Their leading drug, Lorotrectinib, targets TRK fusion proteins (-tinib as a suffix indicates it inhibits tyrosine kinases) and has shown good efficacy in combating several types of cancer with minimal side effects reported. Notable upcoming events are a data review at an upcoming oncology conference October 19-23, Earnings Report on 11/5/18, and a New Drug Application review PDUFA by the FDA on 11/26/2018. The last date is the most important as Loxo could see Lorotrectinib obtain FDA approval. Other possibilities for the PDUFA are an extension of the review or rejection of the drug. From the research reports I have read so far on Lorotrectinib I am doubtful a rejection/denial will happen. I suspect it will either be approved or the review extended and this will depend upon new data, likely to be presented in October.
The chart currently looks bullish to me. There is a clear uptrend long term with us likely in a Wave 2 in Elliot Wave Theory. Mid term price is consolidating in a descending wedge/bull pennant. The safe trade is to buy once price breaks the top of the channel. An aggressive option is to buy when price touches the bottom of the channel. If I buy prior to earnings I will probably trim half my position the day before ER then play the run up to the PDUFA review late November.
***This is not investing advice. I am not an investing professional. Do not invest what you cannot afford to lose. All investors should seek guidance from licensed financial advisers and not random people on the internet.***
AVEO missed earnings - kidney cancer treatment too thinly tradedMedical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
TTNP analysis following the stock as 5 directors purchased hundreds of thousands of stock for the price of 24 cents on sept 21st just as it started to move sideways and broke out of the resistance. It broke out of its strong downward channel, so I'll be monitoring it to see any significant runs. This is also the beginning of a golden cross if im not mistaken.
BLRX-BREAKOUT-UPDATEBLRX had a strong rally today and it's just getting started.
In the related idea my price target was $1.34.
Today's high was $1.78
Check out the weekly chart:
Photo Finish.
$1.34 was 1.618 extension level from Waves 1 & 2.
Since the price-action broke $1.34 we will have an extended 3rd wave.
I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.
Target is hard to predict since its impossible to know what level extending waves will terminate.
I will keep a close eye on the price-action.
Will update.
-AB
BLRX-TRADE TARGETS-LONGBLRX is in the middle of an extending 3rd wave.
Target is $1.34.
If BLRX crosses $1.34 which is likely I will hold and reassess the trade.
-AB
MYL out of the bullish wedge new buy longThe price has closed above the downtrend line started this year with consistent volumes. I opened a buy as I am expecting increasing volume and strenght in the next sessions. Tps are already highlighted on the right.
CKPT - BREAKOUT - UPDATECKPT is breaking out on heavy volume.
Primary Wave 1 Extension
Daily:
Levels:
Target:
ACAD Start to the upside?A possible corrective structure may be completed on NASDAQ:ACAD . This could have big upside potential. If we get a consolidation here I'd love to start trading it on the radar.
TCON Tracon Pharmaceuticals, INC. Massive Gains, High Risk!keeping it simple!
We have seemed to reach the bottom 2$ mark once again, and have indicators of a bounce to the top of the wedge, and possible breakout!
I see the moku cloud turning bullish slightly, and buy signals in this area firing.
We had a weekly sqeeze fire short, which seems to be slowing down right about now, with noticable increased volume over the last week.
TCON is also having a update in 2 days at a conference, which could be a positive. Usually people only meet to update investors with PROGRESS.
High risk trading here, massive potential gains. BIO stocks are locked and loaded!
Happy Trading, debating and speculating!
MNKD - Next Resistance Level 1.5, or Reversal of DownTrendLooking for a resistance level that causes a reversal of trend. You can see the 2.01 resistance level was hit on 9/6, and 9/7 the price fell through to 1.78. If the downward trend continues, the next resistance level to be hit would be 1.5. Substantial sell volume on 9/5, 9/6 and 9/7 could be indicative of a higher likelihood for a trend reversal early next week.
According to Chris Lau at InvestorPlace, a 10 yr discounted cash flow revenue exit model values shares at an average of $2.40, placing the stock at a current discount of 20/25%, assuming revenue increases due to the new partnership with UTHR.
finance.yahoo.com
OVID time to get high.....on gainsPharmaceutical company these are starting to become my new drug. Propah gains to be made! This thing moves fast af! bullish all the way.
BHC close to buy zoneAs showed in the chart $BHC comes from a long bullish flag. Price is reaching the buy zone where the major bullish trendline goes through. It's not yet a buy but we are approching such zone. Strategy: watch and wait.
PGNX TRADE UPDATE POTENTIAL LONG PGNX POTENTIAL LONG
I had made a post on August 28th for a potential long opportunity on this pair. After letting the market play out for a few days it has given me a better structural trade and better looking potential long opportunity for what I like to trade. This pair had made a strong push from the $7.30 price area to the $9.30 price area back in late July to late August. This strong push had been a point of interest for me due to the fact that momentum is a big tell on what the market may potentially do and where it could potentially go, so I waited to see what the pullback entailed. Always remember trading is about probability, nobody could for sure 100% guarantee what the market is going to do next so it's our duty as traders to only trade setups that have a good probability to go in the favor we have analyzed it too. So here is my next thought for this pair.
1D Chart:
*on this time frame chart it had displayed a very strong and healthy push by the buyers back in late July and early into August
*the momentum of the push had been a strong buyer momentum push showing strong interest
*the pullback on the 1D chart by the sellers had been clearly weaker than the push to the upside (better probability)
*once this pair had pulled back almost 100% you can see it started to form an ascending trend line with interest from the buyer
4H Chart:
*on this time frame chart it shows how once the pullback had occurred the buyers started to take interest again by forming an ascending trend line with stronger momentum on the buyer side
*this displays the fact that the buyer may most definitely be still interested in purchasing this pair (now at 100% discount from peak)
*watch how price reacts at this ascending trend line and look for strong buyer interest again at the trend line
Based on the setup of this trade, I dont usually give stop losses because risk is different for every trader, but if price hits 7.50/7.10 price level I would hold off on looking to go long on this pair. But aside from that as long as its above that price and we see that strong buyer interest again look for this stock to make a nice push to the upside.
Remember ALWAYS have a trading plan when approaching the markets. You never want to come into the market unprepared because it will take your $ every single time! ALWAYS make sure to also implement proper risk management never risking more than 2% of trading capital as well as a good risk/reward ratio to make your trades more statistically probable for profit.
Cheers! Keep an eye out !
BLRX - BioLine RX - Promising Biotech with Big upside - LongBLRX
BL-8040 Overview
BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation.
Solid Tumors:
In January 2016, BioLineRx entered into a collaboration with MSD, known as Merck in the U.S. and Canada, in the field of cancer immunotherapy. Based on this collaboration, in September 2016 BioLineRx initiated a Phase 2a study, known as the COMBAT study, focusing on evaluating the safety and efficacy of BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in up to 30 patients with metastatic pancreatic adenocarcinoma. The study is an open-label, multicenter, single-arm trial designed to evaluate the clinical response, safety and tolerability of the combination of these therapies as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity. Partial results will be presented at the 2018 ASCO Gastrointestinal Cancers Symposium (ASCO GI) in January 2018, with top-line results expected in the second half of 2018.
September 2016, BioLineRx entered into a collaboration with Genentech , Inc., a member of the Roche Group , in the framework of which both companies would carry out Phase 1b/2 studies investigating BL-8040 in combination with atezolizumab (TECENTRIQ®), Genentech’s anti-PDL1 cancer immunotherapy, in various solid tumors and hematologic malignancies. Genentech commenced a Phase 1b/2 study for the treatment of pancreatic cancer in July 2017, as well as a Phase 1b/2 study in gastric cancer in October 2017. Genentech expects to commence an additional Phase 1b/2 study in lung cancer by early 2018. In September 2017, BioLineRx initiated a Phase 1b/2 study under this collaboration in acute myeloid leukemia (AML). These studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters.
n March 2015, BioLineRx reported successful top-line safety and efficacy results from a Phase 1 safety and efficacy trial for the use of BL-8040 as a novel stem-cell mobilization treatment for allogeneic bone marrow transplantation at Hadassah Medical Center in Jerusalem.
In March 2016, BioLineRx initiated a Phase 2 trial for BL-8040 for allogeneic stem-cell transplantation, conducted in collaboration with the Washington University School of Medicine, Division of Oncology and Hematology. Initial results of this study announced in March 2017 show that a single injection of BL-8040 mobilized sufficient amounts of cells required for transplantation at a level of efficacy similar to that achieved by using 4-6 injections of G-CSF, the current standard of care. Topline results of this study are now expected in mid-2018, as a result of certain delays in study recruitment in connection with the addition of two sites to the study and the regulatory filings associated therewith.
In August 2017, following a successful meeting with the FDA , BioLineRx announced the filing of regulatory submissions required to commence a randomized, controlled Phase 3 registrational trial of BL-8040 for the mobilization of hematopoietic stem cells, or HSCs, for autologous transplantation in patients with multiple myeloma. The trial is expected to commence by the end of 2017.
In November 2017, BioLineRx disclosed preclinical data supporting BL-8040 as robust mobilizer of hematopoietic stem cells, or HSCs, associated with long-term engraftment. The data will be presented as an oral presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition in Atlanta, GA, taking place in December 2017.
Pre-Clinical Data
In vitro and in vivo data show that BL-8040 binds to CXCR4 at the low nanomolar range (1-10nM) and occupies it for prolonged periods of time (>24h). Characterization of the CXCR4 antagonism action of BL-8040 in comparison to other CXCR4 antagonists revealed that, unlike other compounds from the same class, BL-8040 acts as an antagonist as well as an inverse agonist. This activity leads to decreased autonomous signaling of CXCR4 and suggests activity against constitutively active variants.
BL-8040 inhibits the growth of various tumor types including multiple myeloma, non-Hodgkin’s lymphoma, leukemia, non-small cell lung carcinoma, neuroblastoma and melanoma. BL-8040 significantly and preferentially stimulated apoptotic cell death of malignant cells (multiple myeloma, non-Hodgkin’s lymphoma and leukemias). Significant synergistic and/or additive tumor cell killing activity has been observed in-vitro and in-vivo when tumor cells were treated with BL-8040 together with Rituximab, Bortezomib, Imatinib, Cytarbine, BCL-2 inhibitor ABT-199 and the FLT-3 inhibitor AC-220 (in NHL, MM, CML, AML, and AML-FLT3-ITD models, respectively). BL-8040 also mobilizes cancer cells as well as neutrophils and progenitor cells from the bone marrow to the peripheral blood.
The U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to BL-8040 as a therapeutic for the treatment of AML as well as for stem cell mobilization
BL-8040 is being developed by BioLineRx under a worldwide, exclusive license from Biokine Therapeutics.
1.
Conclusion: The current data demonstrate that BL-8040 induces mobilization of AML blasts from the BM and has sustained receptor occupancy. In addition, a direct effect on AML blast viability has been observed in samples obtained during BL-8040 monotherapy. Importantly, the data suggest a differential effect of BL-8040 monotherapy on AML blasts vs. normal progenitors. BL-8040 was found to be safe and well tolerated at all doses tested to date. The updated results of the dose escalation phase of this ongoing study will be presented.
Source: www.bloodjournal.org
2.
The FDA approved the first immunotherapy drug recently, but the field dates back to 1891, when William Coley, a physician and cancer researcher, observed that some cancer patients infected by Streptococcus bacteria experienced a dramatic and spontaneous improvement. He began injecting the bacteria into his patients, with mixed results.
The treatment was nearly abandoned amid skepticism from Coley’s peers and the advent of radiotherapy and improved surgical techniques.
Today, however, new avenues of immunotherapy research are underway, and the field is considered among the most promising new approaches to cancer treatment, according to Jill O’Donnell-Tormey, CEO and director of scientific affairs at CRI.
Source: www.jta.org
3.
"activated with human interleukin 2, or activated against patients own tumor cells in the laboratory, when such are available – have been extremely successful in killing every last cancer cell in the patients. The theory is the same, in that the cells are trained to act as honing devices."
“It’s fantastic because they all were expected to have been dead long ago,” Slavin told ISRAEL21c. “When the laboratory-treated and separated NK cells are infused into a patient, they go immediately to work because they were already trained in the laboratory to become professional killer cells capable of recognizing and destroying foreign cells.”
"The new procedure has little or no side effects, is done during fifteen-minute outpatient intravenous infusion and has already showed promising results in high risk patients with metastatic or resistant cancer."
"In order for the procedure to be government-approved, a much larger number of patients must successfully undergo treatment."
"The reason I am optimistic is because we use mother nature’s tool – immune-system-cells to fight off disease. Normally too, it is the immune system that can recognize cancer cells as undesirable, and under normal circumstances, it will go on an attack until the single abnormal cell, which can grow to a bitter enemy, is gone. In patients with cancer, the patient’s own immune system failed to recognize the enemy and this is why we use the immune system cells from another individual that can easily recognize and destroy such tumor cells escaping the attention of patient’s immune system,” said Slavin."
Summary Source: seekingalpha.com
In two January ASCO presentations, BL-8040 showed robust infiltration of anti-tumor T-cells into liver metastases in pancreatic cancer and primes the tumor micro-environment to enhance the effectiveness of immunotherapy agents.
New oncology asset AGI-134 induced complete tumor regression in 50% and 67% of two mice melanoma preclinical studies. The company plans to start Phase 1/2a clinical trials in 1H 2018.
BiolineRx is funded to 2020 with $55M in cash, no debt. However cash balance might be higher since it's likely company was selling against a $30M ATM since November.
The company has plans to deliver up to a dozen high-potential catalysts in 2018 following a busy January (4 conferences, and 4 clinical data).
Institutional ownership has increased from 20% to almost 60% in a year. Five analysts have a consensus Buy rating with $3.5/share price target.
Chart Screenshots:
screenshots.firefox.com
screenshots.firefox.com
screenshots.firefox.com
Will update.
-AB
PGNX POTENTIAL LONG PGNX POTENTIAL LONG
1W Chart:
* on the weekly chart if you look at recent data it is displaying the fact that the recent buyers are a lot stronger than the sellers
*one candle up from the buyer took out 6 candles down from the sellers
1D Chart:
*on this chart it is displaying the fact that the recent buyer had pushed price up above 4H structure and seems to be holding above this level
*the momentum on the daily chart also favors the buyers, giving us a higher probability for the long side trades
4H Chart:
* on this chart it is displaying that price has broken recent significant structure and has been holding above this level
* yesterdays candles display a weak re-test by the sellers into that recent 4H structure point
1H Chart:
*use this time frame for accuracy of entry as well as risk (stop loss)
ALWAYS have a strategic trading plan when approaching the markets. You want to stay disciplined to your plan no matter what the conditions are. ALWAYS remember trading is about probabilities, nobody knows with 100% certainty what the market will do next but with good probabilities on your side as well as proper risk management it could lead to a profitable and consistent path of trading.
Cheers! Keep an eye out! PLEASE like and follow me here on TradingView for more setups!
Teva still positive but...$Teva is still positive in the uptrend although the candle of yesterday has turned some indicators in bearish position. Over the mid term bullish trend is still strong. Having said that next candles have to be monitored because on a monthly basis there is a potential dragon fly bearish, thus a prompt recover toward the upper edge of the bullish flag is important for further climb. I will keep the chart under observation in the next days.
